July 2026– date –
-
Vertex’s CRISPR Gene Therapy CASGEVY Gains Expanded FDA Approval for Sickle Cell Disease and Beta Thalassemia in Children Ages 2 and Older
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced the US FDA has approved an expanded indication for its gene therapy, CASGEVY® (exagamglogene autotemcel), for treating sickle cell disease or transfusion-dependent beta... -
UniXell’s iPSC-Derived Parkinson’s Therapy UX-DA003 Cleared for US Clinical Trials by FDA
Parkinson's News Today USA Overview UniXell Biotechnology has received FDA Investigational New Drug (IND) clearance for UX-DA003, an allogeneic iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson's disease, enabling th... -
KATU News: Experimental Gene Therapy Targeting Aging Cells Based on Yamanaka Factors Enters Early Glaucoma Trials
KATU News (YouTube) USA Overview According to KATU News, an experimental gene therapy inspired by Professor Shinya Yamanaka's Nobel Prize-winning iPSC research is targeting aging cells and holds the potential to open a new chapter in agi... -
Amerigo Scientific Unveils Advanced iPSC-Derived Cells to Propel Biomedical Research and Cell Therapy
24-7PressRelease.com (Amerigo Scientific発表) USA Overview Amerigo Scientific has launched a new portfolio of high-purity, iPSC-derived cells, including advanced reporter lines, aimed at accelerating biomedical research and cell therapy ... -
CAR T-Cell Therapy Expands to Autoimmune Diseases: Preliminary Data Reported from ~300 CD19-Targeted Treatments
RheumNow.com USA Overview CAR T-cell therapy is now being actively investigated not only for specific blood cancers but also as a treatment for autoimmune diseases such as systemic lupus erythematosus (SLE). As of May 2026, preliminary d... -
Exosome Clinical Trials Hit ~90 Globally in 2026: Advancing Regenerative Medicine, Diagnostic Biomarkers, and Drug Delivery
OmniGenix USA Overview A new peer-reviewed analysis in 2026 reveals approximately 90 exosome-related human clinical trials registered globally, showcasing diverse applications from cancer diagnostics to joint repair. Exosomes are being i... -
Penn Medicine’s AI Framework Uncovers Novel GPNMB Target for CAR T-cell Therapy, Advancing Solid Tumor Treatment
Penn Medicine USA Overview Researchers at Penn Medicine have developed an innovative artificial intelligence (AI)-powered framework to efficiently identify novel target antigens for CAR T-cell therapy. This AI framework successfully demo... -
GCAR1: Engineered CAR T-Cells Breakthrough Against Solid Tumors, Showing Promise in Sarcoma
News-Medical.net (University of Calgary発表) Canada Overview Researchers from the University of Calgary and McMaster University have developed GCAR1, an experimental CAR T-cell therapy targeting a novel glycoprotein uniquely expressed in... -
CAR-NK Cell Therapy for Solid Tumors: Promising Safety and Off-the-Shelf Potential Outpace CAR-T
Cell Reports Medicine (via PubMed) USA Overview A new review highlights chimeric antigen receptor (CAR)-modified natural killer (NK) cells as a promising immunotherapy strategy for solid tumor treatment. Compared to CAR-T cell therapy, C... -
Europe’s Biotech Vanguard: Automated, Closed Systems Drive Next-Gen CGT Manufacturing and Decentralized Access
PharmTech.com ヨーロッパ Overview European biotechnology firms are pioneering next-generation manufacturing technologies for cell and gene therapies (CGT), centered on automated, closed systems. These innovations, exemplified by companie...
